- Ferring Pharmaceuticals A/S, based in Copenhagen Denmark, with offices world-wide,
has entered into a 4-year agreement to license Target Health's new Internet-based
Clinical Trial Software. The agreement also includes cooperation with Target Health
Inc. in the development of the software. Ferring has two NDAs approved which used
Target Health's current EDC software, Target e*CRF®.
- Target Health has entered into a 2-year agreement with a prominent biotech company
with multiple clinical candidates
- All our global studies are now solely EDC based - we would never go back to paper.
Our new benchmark for locking a database, once all the information is available
is ONE DAY. Senior Vice President Global Clinical Research & Development
- “Cynthia [lead CRA] - the site looks fantastic!” NG, Pfizer Inc.
- “Hi, I just want to thank you. I know you have been working so hard to meet
our ever-changing, highly-demanding needs, and I just want to let you know how much
we appreciate it. It is a pleasure to be working with you. With kind regards”
Imogene Grimes, Ph.D., Vice President, Biostatistics and Data Management, Regeneron
Pharmaceuticals.
- “Using Target Health's Internet-based clinical trial system, Target e*CRF®,
we are able to monitor device safety in real-time in a high-risk neonates undergoing
cardiac surgery. Its nice to know the status of patient enrollment and data entry
without having to contact the clinical study sites directly.” Eli Pines, Ph.D.
Vice President and Chief Scientific Officer, Synthemed, Inc.
- "With electronic data capture by the Target e*CRF® system, we have been
able to view site activities (data entry, queries, audits) in real time and save
a great deal of time and money through our ability to quickly lock a data base and
perform interim analyses when necessary. With Target Document®, we have been
able to seamlessly manage documents, in a cost-effective way, for a worldwide trial
in pediatrics, without the need of multiple paper copying, email and overnight express
carriers." Benjamin Levinson, MD, Vice President, Drug Development, Wellspring
Pharmaceutical Corporation.
- “My sincere thanks for a job well done. These timelines, I can tell you would
be the envy of 99% of the industry. What a difference hard work and planning makes.”
Patrick O’Connor, Senior Vice President, Global Clinical Research & Development,
Ferring Pharmaceuticals, Copenhagen.
- “Congratulations for the clean file! Clean files are important milestones.
Especially, when they are achieved in a record time and with all documentation so
well-recorded (I guess both issues are usually linked). It should be acknowledged
your enormous effort. It requires dedication and know-how to establish clean file
just 8 days after the LPLV. I really appreciate your efforts, persistence, continued
motivation and drive for excellence.” JCA, MD Executive, Director, Obstetrics
& Gynecology, Clinical Research & Development, Ferring Pharmaceuticals,
Copenhagen.
- "With Target e*CRF®, we have been able to keep completely informed of the
study status any where in the US and were able to do a key interim analysis within
2 days of the final patient measurement.” Sam Lynch, DMD, President, Biomimetic
Pharmaceuticals, Inc.
- “With Target e*CRF®, we were able to utilize a web-based central randomization
schema, which allowed us to stratify and randomize patients across the US, Western
Europe, Eastern Europe and India. We were also able to view data in real time and
anywhere on the globe. This was TESTED and VERIFIED by myself. Marian Gorecki, Ph.D.,
C.E.O., MediWound Ltd, Israel
- As you surely know, we had database lock for our pivotal study CS21 10 days after
LPLV and 3 days after last data available. This extraordinary achievement was doable
thanks to all involved, including you. I wanted also to thank you especially for
always going the extra mile for us whenever needed. Silvana Cappi, Ferring
- I am writing this email to express my sincere thanks to you. I just went through
all scenarios for the visual acuity calculations in 0702 study. No issues are identified.
I sent the scenario table to you and we went over the table in 10/15 minutes. In
contrast, the same table was sent to another vendor, I spent ~20 hours to go through
all situations in details. I still identified over 10 problems this weekend. Thanks
making my life easy!! Senior Clinical Data Manager.
- 1. Dear Jules, You may already have heard about this (via Ferring US), but we finally
got [NDA] approval and launched Repronex on August 11th, 2003. It has been very
busy. My sincere thanks for your contribution as it was vital to the approval. Rick
Jeysman, President, Ferring Canada
- First of all many thanks for sending me the Orphan Drug Designation. Well done from
your side! Dr. Bernd Rosenkranz, VP Clinical Development, Jerini AG
- Many thanks to the whole submission team at Target Health and at Jerini for the
successful and timely Canadian CTA submission, which will be an important step in
getting the US (now US/Canadian) trial done on time. Dr. Bernd Rosenkranz, VP Clinical
Development, Jerini AG
|